KPTI Quote, Financials, Valuation and Earnings

Bruker has a net margin of -82.7% compared to Karyopharm Therapeutics's net margin of 4.73%. Karyopharm Therapeutics's return on equity of -- beat Bruker's return on equity of 19.61%.

Karyopharm Therapeutics has a consensus price target of $4.50, signalling upside risk potential of 526.22%. On the other hand Bruker has an analysts' consensus of $73.80 which suggests that it could grow by 21.42%. Given that Karyopharm Therapeutics has higher upside potential than Bruker, analysts believe Karyopharm Therapeutics is more attractive than Bruker.

Karyopharm Therapeutics has a beta of 0.072, which suggesting that the stock is 92.756% less volatile than S&P 500. In comparison Bruker has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.959%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.33% to investors and pays a quarterly dividend of $0.05 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Karyopharm Therapeutics quarterly revenues are $38.8M, which are smaller than Bruker quarterly revenues of $864.4M. Karyopharm Therapeutics's net income of -$32.1M is lower than Bruker's net income of $40.9M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Bruker's PE ratio is 29.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.62x versus 2.78x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -82.7% compared to Karyopharm Therapeutics's net margin of -104.98%. Karyopharm Therapeutics's return on equity of -- beat Ionis Pharmaceuticals's return on equity of -93.21%.

Karyopharm Therapeutics has a consensus price target of $4.50, signalling upside risk potential of 526.22%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.32 which suggests that it could grow by 83.26%. Given that Karyopharm Therapeutics has higher upside potential than Ionis Pharmaceuticals, analysts believe Karyopharm Therapeutics is more attractive than Ionis Pharmaceuticals.

Karyopharm Therapeutics has a beta of 0.072, which suggesting that the stock is 92.756% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.485%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $38.8M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $133.8M. Karyopharm Therapeutics's net income of -$32.1M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.62x versus 6.08x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -82.7% compared to Karyopharm Therapeutics's net margin of -49.65%. Karyopharm Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Karyopharm Therapeutics has a consensus price target of $4.50, signalling upside risk potential of 526.22%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that Karyopharm Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Karyopharm Therapeutics is more attractive than NovaBay Pharmaceuticals.

Karyopharm Therapeutics has a beta of 0.072, which suggesting that the stock is 92.756% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $38.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Karyopharm Therapeutics's net income of -$32.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.62x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -82.7% compared to Karyopharm Therapeutics's net margin of -2357.27%. Karyopharm Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Karyopharm Therapeutics has a consensus price target of $4.50, signalling upside risk potential of 526.22%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1404.43%. Given that Palatin Technologies has higher upside potential than Karyopharm Therapeutics, analysts believe Palatin Technologies is more attractive than Karyopharm Therapeutics.

Karyopharm Therapeutics has a beta of 0.072, which suggesting that the stock is 92.756% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $38.8M, which are larger than Palatin Technologies quarterly revenues of $350K. Karyopharm Therapeutics's net income of -$32.1M is lower than Palatin Technologies's net income of -$7.8M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.62x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.